Novavax, Inc. (NVAX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EST
Pre-market:
| Previous close | 12.01 |
| Open | 11.69 |
| Bid | 11.00 x 1000 |
| Ask | 11.41 x 1300 |
| Day's range | 11.18 - 12.28 |
| 52-week range | 8.75 - 101.39 |
| Volume | |
| Avg. volume | 7,002,121 |
| Market cap | 954.595M |
| Beta (5Y monthly) | 1.75 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -17.51 |
| Earnings date | 27 Feb 2023 - 03 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 55.33 |
- Motley Fool
Better Buy: Novavax or BioNTech Stock?
The two companies, known for their vaccines, could see their businesses benefit from a yearly COVID-19 shot.
- Yahoo Finance
COVID is 'pretty much out of the models' for pharma companies: Wells Fargo analyst
Companies whose businesses were buoyed or boosted by Covid product demand are facing a cliff in 2023, and will have to pivot to more traditional strategies.
- Motley Fool
1 Reason to Buy Novavax in 2023 and 2 Reasons to Sell
Novavax (NASDAQ: NVAX) has offered investors just such a ride over the past few years. Initial gains came as investors bet on Novavax's chances of bringing a coronavirus vaccine to market; declines occurred after the vaccine entered the market later than rival products did. Now, as we start a new year, you might be wondering what to do about Novavax.
© 2023 Yahoo. All rights reserved.
